Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2014 1
2017 2
2018 2
2019 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; monarchE Committee Members. Johnston SRD, et al. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Clinical Trial.
At 4 years, the absolute difference in invasive disease-free survival between the groups was 6.4% (85.8% [95% CI 84.2-87.3] in the abemaciclib plus endocrine therapy group vs 79.4% [77.5-81.1] in the endocrine therapy alone group). 157 (5.6%) of 2808 patients in the …
At 4 years, the absolute difference in invasive disease-free survival between the groups was 6.4% (85.8% [95% CI 84.2-87.3] in the abemacicl …
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators. Aebi S, et al. Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16. Lancet Oncol. 2014. PMID: 24439313 Free PMC article. Clinical Trial.
Patients with oestrogen-receptor-positive ILRR received adjuvant endocrine therapy, radiation therapy was mandated for patients with microscopically involved surgical margins, and anti-HER2 therapy was optional. ...FUNDING: US Department of Health and …
Patients with oestrogen-receptor-positive ILRR received adjuvant endocrine therapy, radiation therapy was mandated for …
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
Hodge JW, Guha C, Neefjes J, Gulley JL. Hodge JW, et al. Oncology (Williston Park). 2008 Aug;22(9):1064-70; discussion 1075, 1080-1, 1084. Oncology (Williston Park). 2008. PMID: 18777956 Free PMC article. Review.
The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. ...This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well …
The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. ...This …
Systemic Therapy for Lung Cancer Brain Metastases.
Pellerino A, Bruno F, Rudà R, Soffietti R. Pellerino A, et al. Curr Treat Options Oncol. 2021 Oct 25;22(12):110. doi: 10.1007/s11864-021-00911-7. Curr Treat Options Oncol. 2021. PMID: 34693454 Review.
Systemic therapy for brain metastases (BM) is quickly moving from conventional cytotoxic chemotherapy toward targeted therapies, that allow a disruption of driver molecular pathways. ...Moreover, these drugs may delay the use of local therapies, such as stereotactic radios …
Systemic therapy for brain metastases (BM) is quickly moving from conventional cytotoxic chemotherapy toward targeted therapies, that …
Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?
Bernier J. Bernier J. Nat Clin Pract Oncol. 2005 Jun;2(6):305-14. doi: 10.1038/ncponc0201. Nat Clin Pract Oncol. 2005. PMID: 16264988 Review.
In an attempt to improve treatment outcome, several teams recently investigated the role of altered fractionation radiotherapy in conjunction with systemic chemotherapy. The controlled trials that investigated this combined approach indicate that, although the magnitude of …
In an attempt to improve treatment outcome, several teams recently investigated the role of altered fractionation radiotherapy in con …
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Kimura T, Nagata Y, Chayama K. Kodama K, et al. Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9. Oncology. 2018. PMID: 29428943
OBJECTIVE: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). ...
OBJECTIVE: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib m …
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Colleoni M, et al. Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17. Lancet Oncol. 2018. PMID: 29158011 Clinical Trial.
We enrolled postmenopausal women of any age with hormone receptor-positive, lymph node-positive, and operable breast cancer for which they had undergone local treatment (surgery with or without radiotherapy) and had completed 4-6 years of adjuvant endocrine therapy. …
We enrolled postmenopausal women of any age with hormone receptor-positive, lymph node-positive, and operable breast cancer for which they h …
11 results